

autoantibody selected from the group consisting of [SCH 94.03,] SCH 79.08, 01, 04, A2B5, HNK-1, antigen binding fragments thereof, and isolated or synthetic autoantibody capable of inducing remyelination of central nervous system axons.

2. (Amended) The method of Claim 1 or 20 wherein the method of administration is intravenous administration.
3. (Amended) The method of Claim 1 or 20 wherein the method of administration is intraperitoneal administration.
4. (Amended) The method of Claim 1 or 20 wherein said amount of monoclonal antibody administered is between from about 0.5 mg/kg to about 400 mg/kg.

9. (Amended) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of an autoantibody selected from the group consisting of [SCH 94.03,] SCH 79.08, 01, 04, A2B5 and HNK-1, antigen binding fragments thereof, and isolated or synthetic autoantibody capable of inducing remyelination of central nervous system axons.

10. (Amended) The method of Claim 9 or 21 wherein said mammal is a human being having multiple sclerosis, or a human or domestic animal with a viral demyelinating disease, or a post-neural disease of the central nervous system.
11. (Amended) The method of Claim 9 or 21 wherein the method of administration is intravenous administration.
12. (Amended) The method of Claim 9 or 21 wherein the method of administration is intraperitoneal administration.

94 13. (Amended) The method of Claim 9 or 21 wherein said amount of monoclonal antibody administered is between from about 0.5 mg/kg to about 400 mg/kg.

14. (Amended) The method of Claim 9 or 21 wherein said mammal is a mouse infected with Strain DA of Theiler's murine encephalomyelitis virus.

F-3  
95 19. (Amended) A pharmaceutical composition comprising as the active agent, [an antigen binding fragment of] an autoantibody selected from the group consisting of an antigen binding fragment of [SCH 94.03, SCH 79.08, and HNK-1]; and isolated or synthetic autoantibody capable of inducing remyelination of central nervous system axons.

Please add the following claims:

F-3  
E-8 --20. A method of stimulating remyelination of central nervous system axons in a mammal which comprises administering to said mammal an effective amount of an autoantibody selected from the group consisting of SCH 94.03 and antigen binding fragments thereof.

21. A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of an autoantibody selected from the group consisting of SCH 94.03 and antigen binding fragments thereof.--

#### REMARKS

The foregoing amendments and the following remarks are submitted for consideration by the Examiner prior to examining the instant Application.